Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 17/20 | 0.83 |
| ▸ | CNR2 | P34972 | 4/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1381069 | 0.84 | CNR1 (0.84) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1379605 | 0.84 | CNR1 (0.84) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1382696 | 0.84 | CNR1 (0.86) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1380507 | 0.83 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13083368 | 0.81 | CNR1 (0.56) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL4690869 | 0.76 | CNR1 (0.71) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3371991 | 0.76 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL14252053 | 0.75 | CNR1 (0.73) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13083362 | 0.75 | CNR1 (0.72) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL14384564 | 0.74 | CNR1 (0.58) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575901-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | claimed |
| JP-4719469-B2 | — | — | 2011-07-06 | — | — | JP | claimed |
| EP-1575901-A4 | SUBSTITUTED AMIDES | MERCK & CO INC (US) | 2009-03-18 | — | — | EP | claimed |
| US-7348456-B2 | Substituted amides | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | claimed |
| US-20060106071-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | claimed |
| JP-2006510716-A | — | — | 2006-03-30 | — | — | JP | claimed |
| EP-1575901-A2 | SUBSTITUTED AMIDES | Merck & Co., Inc. (a New Jersey corp.) (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058145-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2004-07-15 | — | — | WO | claimed |
| EP-1575901-B1 | SUBSTITUTED AMIDES | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| US-7576239-B2 | Substituted amides | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576239-B2 | Substituted amides | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576239-B2 | Substituted amides | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090137529-A1 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-05-28 | — | — | US | disclosed |
| US-20080194645-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080194645-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-20080194645-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2008-08-14 | — | — | US | disclosed |
| US-7348456-B2 | Substituted amides | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348456-B2 | Substituted amides | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348456-B2 | Substituted amides | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060106071-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106071-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1591/4885 |
| US-20080194645-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1591/4885 |
| US-20090137529-A1 | SUBSTITUTED ESTERS AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, CHRNA10 | CNR1 1/4885CNR2 2/4885CYP2D6 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.